On November 10, Wuhan Landing Med, a medical AI enterprise, officially announced that it had completed the round-D financing of RMB 320 million, which was led by Ali Health and followed by Ether Capital. Huaxing Capital acted as the exclusive financial advisor for this round of transactions.

Landing Med is a high-tech enterprise that uses 5G + AI cloud diagnosis technology to provide overall solutions for pathological diagnosis. With the forward-looking layout of the whole chain, product services cover sample production and scanning, AI cloud diagnosis and the whole process quality monitoring of the laboratory. Landing has realized the digital management of the whole industry chain and artificial intelligence cancer cell diagnosis to ensure the accuracy and efficiency of AI pathological diagnosis with data closed loop.

Pathological examination is the gold standard for tumor diagnosis. The domestic pathological market is about 50 billion, of which cellular pathology accounts for 75%. However, there is an extreme shortage of pathologists in China. There is one pathologist among 11, 000 people in the United States, while there is one pathologist among 136, 000 people in China. The density of pathologists in China is less than 10% of that in the United States. In addition, the distribution of domestic pathologists is very uneven, most of them are in class III hospitals, and the number of registered pathologists in domestic first-class hospitals is less than 1% of China's overall pathologists. Therefore, the State encourages pathologists to practice at multiple points and use AI to improve the efficiency and accuracy of pathological diagnosis.

Focusing on the urgent clinical needs in the field of Pathology, Landing shares took the lead in realizing the diversified multi-level business closed-loop mode of "equipment plus consumables plus service", created a new era of automation, intelligence, data and standardization of cervical cancer screening by using the independently developed artificial intelligence cancer cell diagnosis technology in domestic and abroad, and established an expert sharing, capability sharing and The Belt and Road Initiative of cancer screening, is the resource sharing cervical cancer screening platform. Its artificial intelligence cytology cervical cancer screening technology has been widely applied in 30 provinces and autonomous regions in China for many years and has entered the countries of Malaysia, Indonesia and Pakistan. Landing has 12 subsidiaries and established 5 large-scale artificial intelligence laboratories and 67 small and medium-sized artificial intelligence laboratories in China. The company has completed AI cloud diagnosis and screening for millions of people from across the country, and the products have been used by more than 600 general hospitals.